OmniSeq
Buffalo
About OmniSeq
OmniSeq offers physicians and their patients of the most actionable tumor-profiling information possible. OmniSeq, an innovation of Roswell Park Cancer Institute, is a molecular diagnostic laboratory. It endeavors to find the right drug or the right trial for every patient. It also offers NY State CLEP approved assays, including OmniSeq Comprehensive, a 144 gene NGS assay that covers almost all known genetic alterations associated with an FDA-approved targeted therapy or genotype directed clinical trial. OmniSeq is also making significant investments to create better diagnostics for immuno-oncology therapy selection. The company was founded in 2015 and is based in Buffalo, New York.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $11.6M
- Funding stage: M&A
- Last round: Series Unknown (Jun 2019)
- Website: omniseq.com
- Phone: 1(800)781-1259
Industries & Categories
Biopharma, Biotechnology, Clinical Trials, Health Care, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/omniseq-129448 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.